West Pharmaceutical Services WST EV / EBITDA
EV / EBITDA at other companies
Other financials
Where this comes from
Calculated from West Pharmaceutical Services’s reported figures.
Based on the most recent quarter.
The official record: West Pharmaceutical Services’s 10-Q, filed April 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about West Pharmaceutical Services's ev / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is West Pharmaceutical Services's EV / EBITDA?
- West Pharmaceutical Services (WST) reported EV / EBITDA of 21.5× in Q1 2026.
- How has West Pharmaceutical Services's EV / EBITDA changed year-over-year?
- West Pharmaceutical Services's EV / EBITDA decreased by 4.7% year-over-year, from 22.6× to 21.5×.
- What is the long-term trend for West Pharmaceutical Services's EV / EBITDA?
- Over 4 years (2021 to 2025), West Pharmaceutical Services's EV / EBITDA has grown at a -11.0% compound annual growth rate (CAGR), from 149.8× to 94.1×.
- What does EV / EBITDA mean?
- What the whole business (debt included) costs relative to its operating cash earnings.
- How do you interpret EV / EBITDA?
- Lets you compare companies with different leverage and tax positions on a like-for-like basis — the standard multiple in M&A. Lower can mean cheaper, subject to growth and capital intensity.
- How does EV / EBITDA compare across companies?
- Broadly comparable across non-financial sectors; not used for banks and insurers, where EBITDA is not meaningful.